{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:26:00Z","timestamp":1783653960303,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023MD734123"],"award-info":[{"award-number":["2023MD734123"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102376"],"award-info":[{"award-number":["82102376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jmii.2025.04.005","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T19:31:41Z","timestamp":1746905501000},"page":"728-734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The synergistic effect of imipenem combined with ceftazidime-avibactam against Klebsiella pneumoniae with alternating resistance to CZA and carbapenem"],"prefix":"10.1016","volume":"58","author":[{"given":"Yun-Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9875-1982","authenticated-orcid":false,"given":"Di","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2025.04.005_bib1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1128\/AAC.45.4.1151-1161.2001","article-title":"Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae","volume":"45","author":"Yigit","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.04.005_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jgar.2021.02.020","article-title":"A global perspective on the convergence of hypervirulence and carbapenem resistance in Klebsiella pneumoniae","volume":"25","author":"Lan","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jmii.2025.04.005_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.37201\/req\/s01.09.2022","article-title":"Ceftazidime-avibactam","volume":"35","author":"Sanz Herrero","year":"2022","journal-title":"Rev Esp Quimioter"},{"issue":"3","key":"10.1016\/j.jmii.2025.04.005_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106111","article-title":"Assessment of the in vitro activity of ceftazidime\/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017)","volume":"56","author":"Rossolini","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2025.04.005_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2023.106090","article-title":"Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis","volume":"179","author":"Karampatakis","year":"2023","journal-title":"Microb Pathog"},{"key":"10.1016\/j.jmii.2025.04.005_bib6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime-avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jmii.2025.04.005_bib7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/1471-2164-12-402","article-title":"BLAST Ring Image Generator (BRIG): simple prokaryote genome comparisons","volume":"12","author":"Alikhan","year":"2011","journal-title":"BMC Genom"},{"key":"10.1016\/j.jmii.2025.04.005_bib8","series-title":"Antibiotics in Laboratory Medicine","author":"Ameterdam","year":"2015"},{"key":"10.1016\/j.jmii.2025.04.005_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0021-9258(18)65573-5","article-title":"Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites","volume":"208","author":"Elion","year":"1954","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jmii.2025.04.005_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla(KPC-3) mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.04.005_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/1573396314666180308150908","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: novel therapy for multidrug resistant gram negative infections in children","volume":"14","author":"Rodriguez","year":"2018","journal-title":"Curr Pediatr Rev"},{"key":"10.1016\/j.jmii.2025.04.005_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.04.005_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciy576","article-title":"Ceftazidime\/avibactam, meropenem\/vaborbactam, or both? Clinical and formulary considerations","volume":"68","author":"Pogue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.04.005_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00447-22","article-title":"Klebsiella pneumoniae carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview","volume":"66","author":"Hobson","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.04.005_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10096-021-04388-y","article-title":"Interplay between Klebsiella pneumoniae producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report","volume":"41","author":"Arcari","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jmii.2025.04.005_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01714-21","article-title":"Multiple novel ceftazidime-avibactam-resistant variants of bla(KPC-2)-Positive Klebsiella pneumoniae in two patients","volume":"10","author":"Shi","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jmii.2025.04.005_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00079-17","article-title":"In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jmii.2025.04.005_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107213","article-title":"Emergence of ceftazidime-avibactam resistance through in-vivo blaKPC-2 to blaKPC-33 conversion during treatment of ST11 Klebsiella pneumoniae associated infections","volume":"64","author":"Lai","year":"2024","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jmii.2025.04.005_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2024.116372","article-title":"In vivo emergence of cefiderocol and ceftazidime\/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime\/avibactam -based therapies","volume":"110","author":"Amadesi","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jmii.2025.04.005_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02124-21","article-title":"Different conformations revealed by NMR underlie resistance to ceftazidime\/avibactam and susceptibility to meropenem and imipenem among D179Y variants of KPC \u03b2-lactamase","volume":"66","author":"Taracila","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.04.005_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jmii.2023.01.017","article-title":"Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli","volume":"56","author":"Zeng","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2025.04.005_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/8755122520934726","article-title":"Review of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem\/cilastatin-relebactam to target Klebsiella pneumoniae carbapenemase-producing enterobacterales","volume":"36","author":"Hayden","year":"2020","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.jmii.2025.04.005_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02179-21","article-title":"Klebsiella pneumoniae mutants resistant to ceftazidime-avibactam plus aztreonam, imipenem-relebactam, meropenem-vaborbactam, and cefepime-taniborbactam","volume":"66","author":"Satapoomin","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.04.005_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.04.005_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106777","article-title":"Ceftazidime-avibactam-based combination therapy for hospital-acquired central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae","volume":"61","author":"Zhao","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2025.04.005_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jgar.2023.03.012","article-title":"Ceftazidime\/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations","volume":"33","author":"Oliva","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.jmii.2025.04.005_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02740-21","article-title":"Synergistic activity of imipenem in combination with ceftazidime\/avibactam or avibactam against non-MBL-producing extensively drug-resistant Pseudomonas aeruginosa","volume":"10","author":"Zhang","year":"2022","journal-title":"Microbiol Spectr"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225000854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225000854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:32:10Z","timestamp":1765485130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118225000854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1684118225000854"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2025.04.005","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The synergistic effect of imipenem combined with ceftazidime-avibactam against Klebsiella pneumoniae with alternating resistance to CZA and carbapenem","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2025.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}